Research and Factsheets

Research

2025

Capital Access Group - FDA extends use of XENOVIEW® to 6-year-olds
2 June 2025 (PDF - 412KB)

CAG-Research-Note-2-June-2025

2025

Capital Access Group - FY24 results - sales growth guidance reiterated
8 May 2025 (PDF - 544KB)

POLX-FY24-results-080525

2025

Capital Access Group - Investor update presentation confirms thesis
13 March 2025 (PDF - 262KB)

POLX-CAG-Investor-update-130325

2025

Capital Access Group - FY24 update - Xenon MRI pharma research collaboration
10 March 2025 (PDF - 262KB)

POLX-CAG-Pharma-collaboration

2025

Capital Access Group - FY24 update - Even better than expected
27 February 2025 (PDF - 540KB)

POLX-CAG-FY24-update

Factsheets

2024

Company Summary
December 2024 (PDF - 1.2MB)

POLX two pager thumbnail

Latest News

Promotion & Sales Representative Agreement
24 June 2025
Result of AGM
09 June 2025
FDA expands XENOVIEW® indication to include children from six years of age
02 June 2025

About Us

Share Price

-

GBp

-

-

-

Annual Report & Account 2021 (inc. Notice of AGM)

Latest Annual Report

Important Dates

Important dates

09 Jun

Annual General Meeting

08 May

Final Results

Investor Alert

Sign up for Email Alerts